HEALTH

Saidal aims to export equivalent of 5% of its turnover

ALGIERS- The public pharmaceutical group Saidal aims to reach, in the next few years, an export level equivalent to around 5% of its turnover, the group's CEO Fatoum Akacem said Wednesday in Algiers.

"Our purpose is to achieve an export level equivalent to around 5% of Saidal's turnover," said Akacem in the hearing before the Committee on Economic, Industry, Trade and Planning Affairs of the People's National Assembly.

This objective, she said, would be achieved notably in view of "the Group's high production capacity" which will enable it to cover the domestic market's needs and to export.

She underlined that the year 2023 will be that of the registration of medicines at the level of several African and Arab countries as a first phase, before setting up "a real export process" as from next year.

Saidal's CEO announced the launch, within less than a month, on behalf of the public laboratory, the first bioequivalence centre in Algeria, adding that other projects will be (re) launched in 2023.

The factory of Medea, destined to the production of raw material, and which was at a standstill for 15 years, will be relaunched within two to three months, said Fatoum Akacem.

Saidal factory of Constantine will start producing insulin during the first quarter of this year.

Saidal will start, this year, producing anti-cancer medicines in full process mode, according to the official.